Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemiaMasamichi Mori, Sadao Kuromitsu|Investigational New Drugs|2017Cited by 254
Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer CellsNaoki Kaneko, Masamichi Mori|Biological and Pharmaceutical Bulletin|2013Cited by 21